156 related articles for article (PubMed ID: 25121956)
1. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
Pommier AJ; Shaw R; Spencer SK; Morgan SR; Hoff PM; Robertson JD; Barry ST; Jürgensmeier JM
Br J Cancer; 2014 Oct; 111(8):1590-604. PubMed ID: 25121956
[TBL] [Abstract][Full Text] [Related]
2. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
[TBL] [Abstract][Full Text] [Related]
4. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
[TBL] [Abstract][Full Text] [Related]
5. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
Spencer SK; Pommier AJ; Morgan SR; Barry ST; Robertson JD; Hoff PM; Jürgensmeier JM
Br J Cancer; 2013 Nov; 109(11):2765-73. PubMed ID: 24149180
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
7. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
8. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
Bar J; Spencer S; Morgan S; Brooks L; Cunningham D; Robertson J; Jürgensmeier JM; Goss GD
Clin Colorectal Cancer; 2014 Mar; 13(1):46-53. PubMed ID: 24355210
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
Bar J; Ding K; Zhao H; Han L; Laurie SA; Seymour L; Addison CL; Shepherd FA; Goss GD; Dimitroulakos J; Bradbury PA
Clin Lung Cancer; 2015 Nov; 16(6):e189-201. PubMed ID: 26081815
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
Zhou C; Taylor S; Tugwood J; Simpson K; Jayson GC; Symonds P; Paul J; Davidson S; Carty K; McCartney E; Rai D; Dive C; West C
Br J Clin Pharmacol; 2019 Aug; 85(8):1781-1789. PubMed ID: 30980733
[TBL] [Abstract][Full Text] [Related]
11. Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.
Pommier AJ; Farren M; Patel B; Wappett M; Michopoulos F; Smith NR; Kendrew J; Frith J; Huby R; Eberlein C; Campbell H; Womack C; Smith PD; Robertson J; Morgan S; Critchlow SE; Barry ST
Cell Metab; 2016 Jan; 23(1):77-93. PubMed ID: 26626460
[TBL] [Abstract][Full Text] [Related]
12. Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.
Kato T; Muro K; Yamaguchi K; Bando H; Hazama S; Amagai K; Baba H; Denda T; Shi X; Fukase K; Skamoto J; Mishima H
Ann Oncol; 2012 Apr; 23(4):933-41. PubMed ID: 21828378
[TBL] [Abstract][Full Text] [Related]
13. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
Cunningham D; Wong RP; D'Haens G; Douillard JY; Robertson J; Stone AM; Van Cutsem E;
Br J Cancer; 2013 Feb; 108(3):493-502. PubMed ID: 23299530
[TBL] [Abstract][Full Text] [Related]
14. Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
Backen AC; Lopes A; Wasan H; Palmer DH; Duggan M; Cunningham D; Anthoney A; Corrie PG; Madhusudan S; Maraveyas A; Ross PJ; Waters JS; Steward WP; Rees C; McNamara MG; Beare S; Bridgewater JA; Dive C; Valle JW
Br J Cancer; 2018 Jul; 119(1):27-35. PubMed ID: 29925934
[TBL] [Abstract][Full Text] [Related]
15. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
16. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
17. Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.
Martin P; Noonan S; Mullen MP; Scaife C; Tosetto M; Nolan B; Wynne K; Hyland J; Sheahan K; Elia G; O'Donoghue D; Fennelly D; O'Sullivan J
BMC Cancer; 2014 Nov; 14():887. PubMed ID: 25428203
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
[TBL] [Abstract][Full Text] [Related]
20. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
Mulders P; Hawkins R; Nathan P; de Jong I; Osanto S; Porfiri E; Protheroe A; van Herpen CM; Mookerjee B; Pike L; Jürgensmeier JM; Gore ME
Eur J Cancer; 2012 Mar; 48(4):527-37. PubMed ID: 22285180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]